Advances in Breast and Gynecologic Cancer Pathology: Molecular Insights and Therapeutic Implications

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 1613

Special Issue Editor

Special Issue Information

Dear Colleagues,

Breast and gynecologic cancers represent a significant burden on global health. According to the most recent cancer statistics by Siegel et al., 2024, breast cancer, lung cancer, and colorectal cancer account for 51% of all new diagnoses, with breast cancer alone accounting for 32% of cases, while uterine corpus cancer accounts for 7% of cases. Advances in molecular pathology and immunohistochemical techniques have revolutionized the diagnosis and treatment of these cancers, leading to improved patient outcomes. This Special Issue aims to explore contemporary research and advancements in breast and gynecologic pathology. We invite original research articles and reviews focusing on:

  • Diagnostic innovations in histopathology and cytopathology.
  • The role of molecular profiling and biomarkers in diagnosing and treating these tumors.
  • Pathophysiological insights into breast and gynecologic tumors.
  • Emerging therapeutic targets and resistance mechanisms.

By addressing these themes, this issue seeks to provide a comprehensive resource for pathologists, oncologists, and researchers dedicated to improving outcomes in breast and gynecologic cancer.

Dr. Hisham Bahmad
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • gynecologic malignancies
  • diagnostic pathology
  • molecular biomarkers
  • histopathology
  • cytopathology
  • prognostic markers
  • targeted therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

24 pages, 7621 KiB  
Review
Unique Molecular Alteration of Lobular Breast Cancer: Association with Pathological Classification, Tumor Biology and Behavior, and Clinical Management
by Huina Zhang and Yan Peng
Cancers 2025, 17(3), 417; https://doi.org/10.3390/cancers17030417 - 27 Jan 2025
Viewed by 1436
Abstract
Invasive lobular carcinoma (ILC), accounting for up to 15% of diagnosed breast cancers, has garnered significant attention due to the loss of the epithelial cell–cell adhesion molecule E-cadherin. This loss contributes to its distinct biological, morphological, and clinical characteristics compared to non-lobular breast [...] Read more.
Invasive lobular carcinoma (ILC), accounting for up to 15% of diagnosed breast cancers, has garnered significant attention due to the loss of the epithelial cell–cell adhesion molecule E-cadherin. This loss contributes to its distinct biological, morphological, and clinical characteristics compared to non-lobular breast cancers. The use of immunohistochemistry (IHC) for E-cadherin and/or the associated cadherin–catenin complex, such as p120-catenin and beta-catenin, in morphologically equivocal cases, has been increasingly adopted in pathology practice. This approach has substantially improved diagnostic accuracy, interobserver reproducibility, and the identification of new morphologic variants of ILC. ILCs exhibit unique tumor biology, which presents considerable challenges in clinical management, especially in preoperative imaging evaluation, surgical management, and neoadjuvant treatment. Recent advances in translational and clinical research have enhanced our understanding of ILC and have spurred the development of new clinical trials specifically targeting these cancers. This review highlights recent progress in various aspects of ILC, including its unique molecular alteration, pathological classification and diagnostic approach, tumor biology and behavior, key clinical management challenges, and ongoing clinical trials, as well as the role of artificial intelligence in diagnosing ILC radiologically and pathologically. The goal of this review is to provide an updated understanding of the tumor biology, clinical manifestations, and molecular landscape of ILC and to help refine current tumor classification and diagnosis, subsequently improving management strategies and overall outcomes for lobular carcinoma patients. Full article
Show Figures

Figure 1

Back to TopTop